4//SEC Filing
Lyssikatos Joseph P 4
Accession 0001967150-26-000001
CIK 0001672619other
Filed
Jan 11, 7:00 PM ET
Accepted
Jan 12, 5:12 PM ET
Size
11.7 KB
Accession
0001967150-26-000001
Insider Transaction Report
Form 4
Lyssikatos Joseph P
CHIEF SCIENTIFIC OFFICER
Transactions
- Sale
Common Stock
[F1][F2][F3]2026-01-08$20.13/sh−7,500$150,962→ 890,188 total(indirect: See footnote) - Sale
Common Stock
[F1][F4][F3]2026-01-08$24.92/sh−33,802$842,474→ 856,386 total(indirect: See footnote) - Sale
Common Stock
[F1][F5][F3]2026-01-09$24.90/sh−41,198$1,025,863→ 815,188 total(indirect: See footnote) - Sale
Common Stock
[F1][F6][F3]2026-01-09$29.13/sh−50,000$1,456,715→ 765,188 total(indirect: See footnote)
Footnotes (6)
- [F1]The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.
- [F2]This transaction was executed in multiple trades at prices ranging from $20.025 to $20.205. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F3]The shares are held by The Lyssikatos Revocable Trust 12/15/2011 for which the Reporting Person serves as trustee.
- [F4]This transaction was executed in multiple trades at prices ranging from $24.90 to $25.065. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F5]This transaction was executed in multiple trades at prices ranging from $24.90 to $24.92. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
- [F6]This transaction was executed in multiple trades at prices ranging from $28.90 to $29.14. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
Signature
/s/ Ben Hohl, by power of attorney|2026-01-12
Documents
Issuer
Enliven Therapeutics, Inc.
CIK 0001672619
Entity typeother
Related Parties
1- filerCIK 0001967150
Filing Metadata
- Form type
- 4
- Filed
- Jan 11, 7:00 PM ET
- Accepted
- Jan 12, 5:12 PM ET
- Size
- 11.7 KB